News

Dec 2024

Poster presentation at British Pharmacological Society (BPS)

Poster on clinical trial at CHDR with title “Intravaginal delivery of oxybutynin via the MedRing OAB: a double-blind three-way crossover study comparing intravaginal and oral oxybutynin administration”.

Nov 2023

Development of Companion App

Smartphone application for iOS & Android for use in a 28-day clinical trial in an out-patient setting.

Feb 2023

First publication in human study

Online publication on LiGalli’s First in Human oxybutynin MedRing study showing favorable vaginal absorption and pharmacokinetics.

Sep 2022

Appointment of Unilever veteran Marga Mathijssen as CEO of LiGalli

Read all about it in our press release.

Apr 2022

First patent granted in Japan

View our certificate of patent.

Jan 2022

LiGalli raises €6.6 million in Series B

Read all about it in our press release.

Dec 2021

Development partner Demcon published an article on LiGalli in their internal Demcon Investment newsletter

You can read the article for more details.

Sept 2021

LiGalli receives the International Life Sciences Award 2021

You can read the article for more details.

Apr 2021

The basic MedRing patent is granted in China

Feb 2021

Stunning results LiGalli first in human study

See press release here.

Nov 2020

LiGalli receives the International Life Sciences Award 2020

See an image of the award here.

Sept 2020

The MedRing Alpha 1.0 is ready

The first in-human trials will start shortly.

June 2020

LiGalli raises €6 million

The LiGalli press release can be found here. The Demcon press release can be found here.

March 2020

The basic MedRing patent is granted

First in the EU, later also in the US.

Feb 2020

The MedRing functional model is ready

The first working (desktop) model of the LiGalli MedRing to proof the working principle.

Dec 2019

The Dutch Government awards LiGalli the MIT subsidy

We look forward to working with our new partner Gimix ('TwentyNext' per July 2022).

History of LiGalli

"Our company owes its name to the 'Li Galli' island group in Italy
- a mythical place where mermaids dwell -
emphasizing women's empowerment, just like our company's products."

Willem de Laat
Founder and Board Member of LiGalli B.V.

Get in touch

Office
Leiden Bio Science Park – BioPartner 1

Address
J.H. Oortweg 21
2333 CH Leiden
The Netherlands

News

History of LiGalli

"Our company owes its name to the 'Li Galli' island group in Italy
- a mythical place where mermaids dwell -
emphasizing women's empowerment, just like our company's products."

Get in touch

Menu

Privacy & Cookies

News

History of LiGalli

"Our company owes its name to the 'Li Galli' island group in Italy- a mythical place where mermaids dwell - emphasizing women's empowerment, just like our company's products."

Get in touch

Menu

Privacy & Cookies

"Our company owes its name to the 'Li Galli' island group in Italy
- a mythical place where mermaids dwell -
emphasizing women's empowerment, just like our company's products."